Indie Asset Partners’s Gilead Sciences GILD Stock Holding History

Indie Asset Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,582	Closed	-$209K	–	123
2020 Q4	$209K	Sell	3,582 -2,313	-39%	-$140K	0.24%	103
2020 Q3	$373K	Buy	5,895 +471	+9%	+$32.7K	0.47%	55
2020 Q2	$372K	Buy	5,424 +591	+12%	+$45.3K	0.47%	58
2020 Q1	$361K	Buy	4,833 +62	+1%	+$4.28K	0.45%	45
2019 Q4	$310K	Buy	+4,771	New	+$311K	0.33%	59

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Indie Asset Partners's GILD Position: Q1 2021 in Review

Indie Asset Partners sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 3,582 shares — an estimated $209K sold.

Indie Asset Partners first reported a position in GILD in Q4 2019 and held it in 5 quarters. The position peaked at $373K in Q3 2020. 1,567 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

Indie Asset Partners reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
Indie Asset Partners sold 3,582 Gilead Sciences shares in Q1 2021, an estimated $209K.
Indie Asset Partners first reported a position in Gilead Sciences in Q4 2019 and held it in 5 quarters.
Indie Asset Partners's Gilead Sciences position peaked at $373K in Q3 2020.
1,567 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on Indie Asset Partners's 13F filing for Q1 2021, filed 13 May 2021.